Sponsors

Wellcome news for Agilent

Agilent Technologies has announced that the Wellcome Trust Case Control Consortium (WTCCC) will standardise the world’s largest human genomic copy number variation (CNV) study on Agilent microarrays. Agilent has also announced that IMGM Laboratories has achieved Certified Service Provider (CSP) status for the Agilent microarray platform.

The Wellcome Trust CNV study aims to determine the genetic causes of certain widespread diseases. The samples will be processed by Oxford Gene Technology (OGT), an Agilent microarray CSP in Oxford. This is an important study of human genetic variation in common diseases, which requires high-resolution microarrays with extremely reproducible performance.

IMGM is one of Europe’s leading genomic service providers and achieved Agilent-certified status after completing training and passing a rigorous series of assessments. These included demonstrating proficiency in, for example, analysing Agilent’s 60-mer oligo microarrays using the complete Agilent system, sample quality control using the Agilent 2100 bioanalyser, sample labelling using Agilent reagents and protocols, and final data analysis using the GeneSpring bioinformatics platform.

www. agilent.com

Latest Issues

GenQA at ESCV 2025

Thessaloniki Concert Hall
17 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025

Diagnostics North East Conference 2025

The Catalyst, Newcastle
3 October